Market revenue in 2023 | USD 159.3 million |
Market revenue in 2030 | USD 450.4 million |
Growth rate | 16% (CAGR from 2023 to 2030) |
Largest segment | Pure prp |
Fastest growing segment | Leukocyte Rich PRP |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pure PRP, Leukocyte Rich PRP |
Key market players worldwide | Johnson & Johnson, Arthrex, Terumo Corp, Zimmer Biomet Holdings Inc, Stryker Corp, EmCyte Corporation, Dr. PRP USA, Juventix Regenerative Medical, APEX Biologix, Celling Biosciences |
Pure prp was the largest segment with a revenue share of 51.73% in 2023. Horizon Databook has segmented the Europe platelet rich plasma (prp) market based on pure prp, leukocyte rich prp covering the revenue growth of each sub-segment from 2018 to 2030.
Europe is the second-largest PRP market globally and is anticipated to witness promising growth during the forecast period. This can be attributed to the rising demand for PRP therapy for sports injuries. In addition, expanding applications of PRP therapy, rapid technological advancements, and progressive demographic aging of the older population contribute to the market growth in Europe.
PRP therapy is regulated under Directive 2001/83/EC of the Council of November 6, 2001, and the European Parliament across the EU. This directive is further adapted by each member as per their regulatory framework. In some European countries, PRP products are considered blood derivatives, as the directive has not been translated into national law across Europe.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account